Objective Establish model of abdominal heterotopic heart transplantation in mice and summarize the experience to provide animal model support for further study of organ transplantation immunology. Methods Inbred BALB/c（n ＝ 30）and C57BL/6（n ＝ 30）mice were selected as donors，and inbred BALB/c（n ＝ 60）mice were used as recipients. The ascending aorta of the donor was anastomosed to the abdominal aorta of the recipient，and the pulmonary artery of the donor was anastomosed to the inferior vena cava of the recipient respectively to establish the heterotopic heart transplantation model. The survival time and the rejection of grafts were observed postoperatively. Results The successful rate of transplantation was 85%（51/60）. The donoroperation time was（7.0±1.0）min，and the recipient operation time was（60±10）min. The vascular anastomosis time was（25±3.0）min. After the transplantation，no immunosuppressive agent was used，and the survival time of the graft was（7.6±0.9）d. The graft on the fifth day，the seventh day showed typical rejection by histopathology. Conclusion Skilled microsurgical techniques and timely management of surgical complications are key to the successful establishment of abdominal heterotopic heart transplantation in mice. 

ObjectiveTo assess the safety and efficacy of direct antiviral drugs （DAAs） inhepatitis C virus （HCV） negative recipients undergoing kidney transplantation from HCV IgG （+） / HCVinfected renal allografts. MethodsA total number of 12 patients were enrolled in the Institute of OrganTransplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from 2018to 2023， including 10 patients who were preemptively started DAAs regimen immediately after transplantation， and 2 patients who were therapeutically given DAAs regimen after abnormal liver function anddetectable viral load. All patients had 12-week oral antiviral regimen of sofosbuvir/velpatasvir （SOF/VEL）. Blood transaminase， serum creatinine， eGFR，drug concentration and HCV viral load were regularly reviewed to evaluate the efficacy and safety of DAAs. ResultsOne case of treatment failure occurred after the completion ofSOF/VEL therapy in 10 preemptively-treated patients， and the genotype was detected as 3b. The other 9 recipients achieved sustained virological response （SVR）12 weeks after the end of SOF/VEL treatment. After altering the antiviral regimen twice in succession， the patients who failed in the initial treatment ultimately achieved SVR12 with a DAAs combination containing ribavirin （RIB）. Abnormal liver function and high HCV viral load were detected in 2 therapeutically treated patients one month after transplantation， the patients had normalized transaminase once SOF/VEL combination was started and achieved SVR12 eventually. The patients who failed to achieve SVR12 showed persistent abnormal bilirubin during the treatment of DAAs containing ribavirin. The serum creatinine and drug concentration of all patients were stable during the follow-up period. ConclusionIt is safe and effective for HCV uninfected recipients to receive HCV-positive kidney grafts with DAAs prophylactic or therapeutic therapy. For patients infected with subtype 3b HCV and failed in the initial treatment of pan-genotypic DAAs regime， a combination of SOF/VEL/RIB is recommended. 

Objective To explore whether temperature changes at different times in the perioperative period correlate with the incidence of early allograft dysfunction（EAD）. Methods Recipients who underwent liver transplantation in the Eastern Theater General Hospital between December 1，2020， and November 30，2023 wereselected， and perioperative clinical data and temperature data at different times of the recipients were collected， andmeaningful body temperature was identified by propensity score matching with other general information data to analyze the correlation of early graft insufficiency with temperature changes. Results There were 86 cases of EAD among 272 recipients， with an incidence of 31.2%. After 1 ：1 propensity score matching， a total of 56 pairs of recipients were matched: divided into the EAD group （n ＝ 56 cases）， and the NO-EAD group （n ＝ 56 instances）. The temperature change 1 h after the opening of the inferior vena cava in the neo-hepatic phase （△ T4 ） was significantly different between the two groups （t ＝ 2.382，P ＝ 0.019）， and with the optimal truncation value of the ROC curve 0.45 ℃， it was foundthat the incidence of EAD in recipients with △ T4lower than 0.45℃ was 2.901 times higher than that higher than 0.45℃（95% CI ＝ 1.181 ～ 7.125，P ＝ 0.020）. Conclusion Temperature change 1 h after opening of the inferior vena cava in the anhepatic phase has a certain correlation with the early graft insufficiency， and the faster the body temperatureincreases， the earlier the early graft function recovers. The quicker the body temperature rises to its normal temperature，the lower the incidence of early graft insufficiency. Intraoperative temperature changes can reflect the recovery of newliver function at an early stage， and the poor rise of body temperature in the new liver stage should arouse the vigilance of clinicians. 

Objective Post-renal transplantation anemia（PTA）occurs frequently in kidney transplant recipients，significantly impacting their quality of life and graft loss. Currently，effective methods to predictthe risk of persistent PTA early post-transplantation are lacking. This study aimed to develop a nomogram prediction model for early persistent PTA specifically tailored to kidney transplant recipients. Methods Using the electronic medical record system of Southern Hospital of Southern Medical University，patient data from January 1，2020 to December 31，2022 were obtained，and 245 subjects were ultimately selected as the research subjects. Among these，85% were randomly selected as the training set for model development，and the remaining 15% constituted the testing set. Using the Least Absolute Shrinkage and Selection Operator（Lasso）regression model，variables potentially affecting early persistent PTA were screened to identify predictive factors.A logistic regression analysis was employed to establish the prediction model. Model performance was assessed using Receiver operating characteristic（ROC）curves，area under the curve（AUC），Calibration plots，and decision Curve Analysis（DCA）. Results Identified predictive factors after screening included recipient's preoperative body mass index，preoperative serum albumin level，preoperative hemoglobin level，preoperative mean corpuscular volume，perioperative use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers，exogenous iron supplementation，and exogenous erythropoietin supplementation. The model demonstrated good discriminativeability with an AUC of 0.87 for the training set and 0.75 for the testing set，indicating robust predictive performance. Calibration and DCA further confirmed the accuracy and clinical utility of the model. Conclusion This nomogram prediction model utilizes early recipient information，including demographic characteristics，laboratory data，and medication regimens，to accurately predict individualized risk of early persistent PTA in kidney transplant recipients. This provides a basis for early clinical intervention，potentially improving patient prognosis and quality of life.